Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 5/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
| ▸ | GJA1 | P17302 | 1/20 | 0.34 |
| ▸ | GJB2 | P29033 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631324 | 1.00 | LGALS8 (0.41) | LGALS8OGAPYGBFGF1GJA1 | |
| SCHEMBL21122324 | 0.86 | OGA (0.39) | LGALS8OGAPYGBFGF1GJA1 | |
| SCHEMBL21530603 | 0.86 | OGA (0.39) | LGALS8OGAPYGBFGF1GJA1 | |
| SCHEMBL13563735 | 0.86 | OGA (0.39) | LGALS8OGAPYGBFGF1GJA1 | |
| SCHEMBL19902013 | 0.86 | OGA (0.39) | LGALS8OGAPYGBFGF1GJA1 | |
| SCHEMBL11915783 | 0.86 | OGA (0.39) | LGALS8OGAPYGBFGF1GJA1 | |
| SCHEMBL23603150 | 0.85 | LGALS8 (0.45) | LGALS8OGAPYGBFGF1SLC5A1 | |
| SCHEMBL21077738 | 0.85 | LGALS8 (0.45) | LGALS8OGAPYGBFGF1SLC5A1 | |
| SCHEMBL22423226 | 0.85 | LGALS8 (0.45) | LGALS8OGAPYGBFGF1SLC5A1 | |
| SCHEMBL12899675 | 0.85 | LGALS8 (0.45) | LGALS8OGAPYGBFGF1SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333545-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 4 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333545-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 4 | NEU4, PA2G4, STT3B | LGALS8 169/4885OGA 1413/4885PYGB 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.